Drug- Eluting Stent for Symptomatic Intracranial Arterial Stenosis

Exclusion Criteria

• •1. History of prior stent implantation or surgical treatment at the target lesion;
• •2. Intracranial hemorrhage within 30 days preoperatively or presence of untreated chronic subdural hematoma ≥5 mm;
• •3. Major surgical procedure within 30 days prior to the procedure;
• •4. Acute ischemic stroke within 14 days prior to the procedure;
• •5. Symptomatic carotid stenosis ≥50% outside the target lesion, or coexisting intracranial/extracranial vascular stenosis ≥70% requiring intervention;
• •6. Severe calcification, significant stenosis, or tortuosity of the target vessel precluding device deployment as assessed by investigators;
• •7. Intracranial tumor, arteriovenous malformation, or tandem aneurysms proximal/distal to the target lesion;
• •8. Non-atherosclerotic stenosis etiology (e.g., arterial dissection, moyamoya disease, vasculitis);
• •9. Cardiac thromboembolic sources (e.g., atrial fibrillation, left ventricular thrombus, myocardial infarction within 6 weeks);
• •10. Uncontrolled hypertension (persistent systolic blood pressure (SBP) ≥180 mmHg or diastolic blood pressure (DBP) ≥110 mmHg);
• •11. Contraindications to antiplatelet/anticoagulant therapy, coagulopathy or bleeding diathesis precluding intervention per investigator judgment;
• •12. Severe comorbidities: cardiac failure (New York Heart Association (NYHA) Class III-IV), respiratory/renal failure (serum creatinine \>3.0 mg/dL (264 μmol/L)), Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) more than 3 times the upper limit of the normal value), active malignancy;
• •13. Hypersensitivity to rapamycin, polylactic-co-glycolic acid, nitinol, platinum-tungsten, anesthetics, or contrast agents;
• •14. Life expectancy \<1 year;
• •15. Pregnancy, lactation, or planned pregnancy within 1 year;
• •16. Concurrent participation in other clinical trials without completing primary endpoint follow-up;
• •17. Cognitive impairment or psychiatric disorders compromising protocol compliance; other exclusionary conditions per investigator discretion.